Not only the effective, but a rapid blood pressure reduction as a novel aim in hypertension treatment. The role of combination therapy

1. Kearney P.M., Whelton M., Reynolds К., et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-223.

2.

3. Cheung B.M.Y., Ong K.L., Man Y.B., et al. Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001-2002. J Clin Hypertens (Greenwich). 2006;8:93-98.

4.

5. Ong K.L., Cheung B.M.Y., Man Y.B., et al. Prevalence, awareness, treatment, and control of hypertension among United States adults1999-2004. Hypertension. 2007;49:69-75.

6.

7. Moser M., Franklin S.F. Hypertension management: results of a new national survey for the Hypertension Education Foundation: Harris Interactive. J Clin Hypertens (Greenwich). 2007;9:316-323.

8.

9. Centers for Disease Control and Prevention (CDC). Prevalence of actions to control high blood pressure-20 states, 2005. MMWR. 2007;56(17):420-423.

10.

11. Moser M., Franklin S.S. Hypertension management: results of a new national survey for the hypertension education foundation: Harris interactive. J Clin Hypertens (Greenwich). 2007;9:316-323.

12.

13. Оганов Р.Г., Шальнова 2006

14.

15. Jamerson K.A., Basile J., Prompt. Aggressive BP Lowering in High-Risk Patients J Clin Hypertens (Greenwich). 2008;10 (suppl l):40-48.

16.

17. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.

18.

19. Dоsing R. Overcoming barriers to effective blood pressure control in patients with hypertension. Curr Med Res Opin. 2006;22:1545-1553.

20.

21. Guidelines

22.

23. Basile J.N., Chrysant S. The importance of early antihypertensive efficacy: the role of angiotensin 11 receptor blocker therapy. J Hum Hypertens. 2006;20:169-175.

24.

25. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.

26.

27. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.

28.

29. Staessen J.A., Thijs L., Fagard R., et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe trial. J Hypertens. 2004;22:847-857.

30.

31. Lithell H., Hansson L., Skoog I., et al, for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): outcomes in patients not receiving add-on therapy after randomization. J Hypertens. 2004;22:1605-1612.

32.

33. Dahlцf B., Sever P.S., Poulter N.R., et al, for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflume-thiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895-906.

34.

35. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.

36.

37. Weber M.A., Julius S., Kjeldsen S.E., et al. Blood pressuredependent and independent effects of antihypertensive treatment onclinical events in the VALUE trial. Lancet. 2004;363:2049-2051.

38.

39. Lithell H., Hansson L., Skoog I., et al., for the SCOPEStudy Group. The Study on Cognition and Prognosis in theElderly (SCOPE): principal results of a randomized double-blindintervention trial. J Hypertens. 2003;21:875-886.

40.

41. l. Jamerson K., Bakris G.L., Dahlцf B., et al., forthe ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007;16:80-86.

42.

43. Philipp T., Glazer R., Wernsing M., et al. Dual calcium channel and angiotensin II receptor blockade is superior to amlodipine or valsartan alone for optimal hypertension control. J Clin Hypertens (Greenwich). 2007;9(suppl A):A39. Abstract P. 83.

44.

45. Philipp T., Smith T.R., Glazer R., et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:563-580.

46.

47. Smith T.R., Philipp T., Vaisse B., et al. Amlodipine andvalsartan combined and as monotherapy in stage 2, elderly, andblack hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich). 2007;9:355-364.

48.

49. Poldermans D., Glazer R., Karagiannis S., et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther. 2007;29:279-289.

50.

51. Trenkwalder et al. DMW 2006;131:S164

52.

53. Izzo et al. J Clin Hypertens 2007 (abstract).

54.

55. Allemann Y., Fraile B., Lambert M. et al. Efficacy of the Combination of Amlodipine and Valsartan in Patients With Hypertension Uncontrolled With Previous Monotherapy: The Exforge in Failure After Single Therapy (EX-FAST) Study. J Clin Hypertens (Greenwich). 2008;10:185-194.

56.

57. Elliott W.J. What Factors Contribute to the Inadequate Control of Elevated Blood Pressure?Clin Hypertens (Greenwich). 2008;10(1 suppl l):20-26.

58.

59. Oliveria S.A., Lapuerta P., McCarthy B.D., et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med. 2002;162:413-420.

60.

61. Margolis K.L., Rolnick S.J., Fortman K.K., et al. Self-reported hypertension treatment beliefs and practices of primary care physicians in a managed care organization. Am J Hypertens. 2005;18(4,ptl):566-571.

62.

63. Ferrari P., Hess L., Pechere-Bertschi A., et al. Reasonsfor not intensifying antihypertensive treatment (RIAT): aprimary care antihypertensive intervention study. J Hypertens.2004;22:1221-1229.

64.

65. Cushman W.C., Ford C.E., Cutler J.A., et al; ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393-404.

66.

67. Bramlage P., Thoenes M., Kirch W., et al. Clinical practice and recent recommendations in hypertension management: reporting a gap in a global survey of 1259 primary care physicians in 17 countries. Curr Med Res Opin. 2007;23:783-791

68.

69. Bangalore S., Kamalakkannan G., Parkar S., et al. Fixed-dose combinations improve medication compliance: a meta-analvsis. Am J Med. 2007;120:713-719.

70.

71. Siegel D., Lopez J., Meier J. Antihypertensive medication adherence in the Department of Veterans Affairs. Am J Med. 2007;120:26-32.

72.

73. Elliott W.J., Meyer P.M. One-year discontinuation rates of antihypertensive drugs in clinical practice: a network meta-analysis [abstract]. J Clin Hypertens (Greenwich). 2007;9:A33.

74.